Drug Type Small molecule drug |
Synonyms + [1] |
Target |
Mechanism KDM1A inhibitors(Lysine-specific histone demethylase 1 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Refractory Ewing Sarcoma | Phase 2 | ES | 27 Jun 2018 | |
Refractory Ewing Sarcoma | Phase 2 | US | 27 Jun 2018 | |
Refractory Ewing Sarcoma | Phase 2 | GB | 27 Jun 2018 | |
Anemia, Sickle Cell | Phase 2 | US | 20 Apr 2017 | |
Hematologic Neoplasms | Phase 2 | US | 05 May 2016 | |
Hematologic Neoplasms | Phase 2 | BE | 05 May 2016 | |
Hematologic Neoplasms | Phase 2 | NL | 05 May 2016 | |
Solid tumor | Phase 2 | BE | 05 May 2016 | |
Solid tumor | Phase 2 | NL | 05 May 2016 | |
Solid tumor | Phase 2 | US | 05 May 2016 |
Phase 1/2 | 70 | (Treatment Group A :100mg of INCB24360) | pxmkhycuef(ywzyvammgk) = owdlprjvba bofkunkvpw (qekgqxifkg, qxwuqqvbcx - nyqddlafyh) View more | - | 05 Mar 2020 | ||
(Treatment Group A :300mg of INCB24360) | pxmkhycuef(ywzyvammgk) = rgeprlnunf bofkunkvpw (qekgqxifkg, zenqkrtlel - yrfymjpftj) View more |